Evidence map›Paper›PMID 36611518›Full record

ArticleHealthcare (Basel, Switzerland)2022

COVID-19 Risk Compensation? Examining Vaccination Uptake among Recovered and Classification of Breakthrough Cases.

Arielle Kaim, Gal Zeevy, Mor Saban

Abstract read
In one paragraph

Article in Healthcare (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Arielle KaimDepartment of Emergency & Disaster Management, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv-Yafo 6139001, Israel.ORCID 0000-0003-1251-3551
Gal ZeevyThe Information & Computerization Unit, The Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Tel-HaShomer, Ramat Gan 5266202, Israel.
Mor SabanHealth Technology Assessment and Policy Unit, The Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Tel-HaShomer, Ramat Gan 5266202, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study has two primary aims: the first is to examine the uptake of COVID-19 vaccination patterns among those previously infected, and the second is an evaluation of the period elapsed between the patient’s latest dose of the vaccine and the infection itself by demographic group. A retrospective study was conducted from 1 March 2020, to 31 May 2022, in Israel. The study found that among Israelis, vaccination uptake following infection is relatively low. When examining gender, one sees that the immunization rate among recovering females is higher than among men. Similarly, differences in uptake exist between age groups. When examining the interval between vaccine dose and infection according to age groups, the most significant breakthrough infection rate is among the ages of 20−59 (1−6 days—0.3%; 7−13 days—0.48%; two to three weeks—0.3%, p < 0.001). This study reveals potential reservoir groups of virus spread. Among previously infected, low vaccination uptake levels are observed (first dose—30−40%, second dose—16−27%, third dose—9% and fourth dose—2%, p < 0.001), despite findings that indicate surging reinfection rates. Among vaccinated, two critical groups (0−19; 20−59) exhibit highest levels of breakthrough cases varying per vaccine doses, with statistically significant findings (p < 0.001). These population groups may be subject to a false sense of security as a result of perceived acquired long-term immunity prompting low perceived risk of the virus and non-vigilance with protective behavior. The findings point to the possibility that individuals engage in more risky health behavior, per the Peltzman effect.

Indexed as

breakthrough casesCOVID-19immunityreinfectionvaccination uptake

Identifiers

PMID36611518
PMCPMC9819034

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.